Skip to main navigation

Contact Us

Investor Relations

Our Company
Product Candidates
- Pipeline
- MultiTAA Therapies
Our Science
Clinical Trials
- Active Clinical Trials
- Expanded Access Policy
Investors/Media
Careers

Investors/Media

Press Releases

Press Releases

Year

Oct 19, 2026

Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer

Sep 22, 2026

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

Mar 18, 2026

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Feb 18, 2026

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 26, 2026

Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology

Jan 05, 2026

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Nov 14, 2025

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 05, 2025

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Nov 03, 2025

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Oct 06, 2025

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 1 - 10 of 128

Investors/Media

Investors/Media Home
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials & Filings
Corporate Governance
Investor Resources

IR and Media Contacts

investor.relations@markertherapeutics.com
(713) 400-6400

©2026 Marker Therapeutics, Inc. All Rights Reserved.

Footer Links

Sitemap
Terms of Use
Privacy Policy